GREEN CROSS

Search
Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
close
Total Menu KOR
close

About usHistory

  • people
    factory
    effect
    people
    people
  • 2016
    License obtained for GC Flu Quadrivalent GC Flu Quadrivalent, the first flu quadrivalent vaccine to be developed in S.Korea, became the second vaccine of its kind in the world to obtain pre-qualification from the World Health Organization (WHO), which will significantly boost the vaccine’s position and competitiveness on the global market.
    2015
    Developed the world’s 4th quadrivalent Influenza Vaccine Green Cross became the first company in Asia and the fourth in the world to obtain a license to produce and distribute its quadrivalent flu vaccine, reaffirming its undisputed position as the leader of vaccine development in Korea.
    2014
    Signed a contract with the The Canadian government for plasma Business project With an eye on the United States, by far the world’s largest market for plasma-derived products, Green Cross set up a biological drug plant in Quebec, Canada.
    2014
    Cumulative total output of flu vaccine by Green Cross exceeds 100 million doses Within only five years of producing its first flu vaccines, Green Cross’ cumulative total output exceeded 100 million doses in 2014.
    2013
    Signed a contract with the Thai Red Cross for plasma fractionation plant project Designing and constructing a biological product plant in Thailand made Green Cross the first Korean pharmaceutical company to export such a facility abroad. The plant is the only plasma fractionation facility of its scale and kind in Southeast Asia, and produces products such as albumin and immunoglobulin.
    2012
    Established wholesaler (Gelinker) in China Green Cross set up Anhui Gelinker Drug Distribution Limited (“Gelinker”) in China, which imports and engages in wholesale distribution of medicines in China.
    2012
    Development of Hunterase and announcement of New Vision 2012 Through joint R&D with Samsung Medical Center in Seoul, Green Cross became the second company in the world to develop a treatment for Hunter syndrome, named Hunterase. Through localized production of this expensive medicine, Green Cross has contributed significantly to the efficiency of the public healthcare system in S.Korea. It has also improved the quality of life for those suffering from Hunter syndrome by increasing their choice of treatment and ensuring a stable supply of medicine.
    2011
    Development of Shinbaro Green Cross developed the Shinbaro Tablet, designed to treat osteoarthritis and the fourth drug to be made of naturally-derived ingredients in S.Korea.
    2010
    Ilsup Huh becomes CEO and chairman After the death of former CEO and chairman, Youngsup Huh, in 2009, Ilsup Huh, then Vice-Chairman, became the new CEO and chairman for Green Cross.
  • people
    factory
    people
  • 2009
    Established Plasma collection centers(GCAM) in the U.S Green Cross set up Green Cross America (GCAM) and acquired two local blood centers. The company has expanded the plasma collection facilities of these centers in an effort to ensure a stable supply of plasma for its pharmaceutical products and to enhance its competitiveness in overseas markets.
    2009
    Completed the first Flu vaccine Plant in S.Korea The Hwasun plant, completed in 2009, became the 12th pharmaceutical factory in the world to succeed in developing a flu vaccine, which has gone on to popularize flu vaccinations in S.Korea and also played a major role in preventing the spread of H1N1 in the country.
    2009
    Completed the largest Plasma Fractionation Plant in Asia Green Cross completed the Ochang plant in 2009, the largest facility in Asia for producing plasma-derived and recombinant products. The plant serves as a forward base from which the company continues to expand its global presence.
    2008
    Developed GreenGene, the world’s 4th recombinant Factor Ⅶ for hemophilia A GreenGene, a new drug for hemophilia A that was developed by Green Cross with genetic recombination technology in 1996, became a catalyst for the company’s global expansion.
    2000
    Urokinase factory established in North Korea Green Cross and its North Korean investment partner made equal investments to set up Jeongseong Green Cross Pharmaceutical Center in North Korea. The Center received significant acclamation as a new model of business cooperation between the two Koreas.
  • people
  • 1995
    Established Green Cross China Green Cross established Anhui Green Cross Bio Products Limited in China in 1995, thereby paving the way for expanding into the local Chinese market for biological products.
    1993
    Developed Suduvax, the world’s 2nd varicella vaccine In December 1994, and in partnership with the Mogam Institute, Green Cross became the first company in S.Korea and the second in the world to develop Suduvax, a varicella vaccine, using the varicella virus prevalent in the nation.
    1992
    Youngsup Huh assumes leadership Mr. Huh became the new company CEO and chairman.
    1990
    Green Cross establishes the s.Korea Hemophilia Foundation (KHF) The KHF mission is to ensure systematic and efficient management of patients with hemophilia—a congenital, hereditary disease—and assist with prevention, treatment and rehabilitation.
    1984
    Establishment of Mogam Institute for Biomedical Research (former Mogam Biotechnology Institute) Intent on returning to Korean society the proceeds it had earned from the success of Hepavax B and helping to improve national public health and welfare, Green Cross, with the approval of the Science & Technology Administration, opened the Mogam Institute, the first nonprofit research foundation to be established by a private-sector entity in S.Korea.
    1983
    Developed Hepavax B, the world’s 3rd Hepatitis B vaccine After 12 years of research and trials, Green Cross became the third pharmaceutical company in the world to develop a hepatitis-B vaccine. Hepavax B played a pivotal role in reducing the prevalence of hepatitis B in S.Korea, which at the time was rampant at 13 percent, to a rate closer to that in developed countries.
  • people
    factory
  • 1974
    Production begins of an antihemophilic factor (AHF) Green Cross also became the first and only company in S.Korea to manufacture an AHF for treating hemophilia-A, which, in an effort to improve public health, was provided free of charge to Red Cross S.Korea until 1980.
    1973
    First in S.Korea to produce urokinase Green Cross began to make a name for itself in S.Korea by manufacturing and exporting urokinase.
    1971
    Produced the nation’s first plasma derived Products After changing its name to Green Cross in 1971, on November 10, 1971, the company partnered with Carter-Wallace, a medicine manufacturer based in the United States, to become the sixth largest pharmaceutical company in the world. After establishing a blood plasma fractionation plant in S.Korea, Green Cross was the first company in S.Korea to manufacture plasma-derived products.
    1967
    Company established Originally founded under the name, “Sudo Microorganism Medical Supplies Company” on October 5, 1967, the company began as a distributor of vaccines and drugs for animals, as well as vaccines against Japanese encephalitis and pertussis for humans. The company then changed its name to “Geukdong Pharmaceuticals” and repositioned itself as a pharmaceutical manufacturer.